Literature DB >> 22982890

Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.

Alex Chang1, Ali Amin, Edward Gabrielson, Peter Illei, Richard B Roden, Rajni Sharma, Jonathan I Epstein.   

Abstract

Distinguishing invasive high-grade urothelial carcinoma (UC) from other carcinomas occurring in the genitourinary tract may be difficult. The differential diagnosis includes high-grade prostatic adenocarcinoma, spread from an anal squamous cell carcinoma (SCC), or spread from a uterine cervical SCC. In terms of metastatic UC, the most common problem is differentiating spread of UC to the lung from a primary pulmonary SCC. Immunohistochemical analysis (IHC) for GATA binding protein 3 (GATA3), thrombomodulin (THROMBO), and uroplakin III was performed on a tissue microarray (TMA) containing 35 cases of invasive high-grade UC. GATA3 IHC was also performed on TMAs containing 38 high-grade (Gleason score ≥8) prostatic adenocarcinomas, representative tissue sections from 15 invasive anal SCCs, representative tissue sections from 19 invasive cervical SCCs, and TMAs with 12 invasive cervical carcinomas of the cervix [SCC (n=10), SCC with neuroendocrine features (n=1), and adenosquamous carcinoma (n=1)]. In addition, GATA3 IHC was performed on representative tissue sections from 15 pulmonary UC metastases and a TMA with 25 SCCs of the lung and 5 pulmonary non-small cell carcinomas with squamous features. GATA3, THROMBO, and uroplakin III were positive in 28 (80%), 22 (63%), and 21 (60%) cases of high-grade UC, respectively. All cases of GATA3-positive staining were nonfocal; 25 (89%) cases demonstrated moderate to strong staining, and 3 (11%) demonstrated weak staining. Of the 7 cases that failed to express GATA3, 5 were positive for THROMBO and/or uroplakin III, whereas 2 were negative for all 3 markers. None of the 38 high-grade prostatic adenocarcinomas was positive for GATA3. Weak GATA3 staining was present in occasional basal cells of benign prostate glands, in a few benign atrophic glands, and in urothelial metaplasia. Of the 15 cases of anal SCCs, 2 (7%) cases showed focal weak staining, and 1 (3%) showed focal moderate staining. Weak staining was also rarely observed in the benign anal squamous epithelium. Of the 31 uterine cervical carcinomas, 6 (19%) showed weak GATA3 staining (3 nonfocal and 3 focal), and 2 (6%) demonstrated focal moderate staining. Twelve (80%) of the metastatic UCs to the lung were positive for GATA3, with 11 cases showing diffuse moderate or strong staining and 1 case showing focal moderate staining. None of the pulmonary SCCs or non-small cell carcinomas with squamous features was GATA3 positive. GATA3 IHC is a sensitive marker for UC, and positive staining in UC is typically nonfocal and moderate or strong in intensity. GATA3 is also highly specific in excluding high-grade prostate adenocarcinoma. Although some cervical and anal SCCs can be GATA3 positive, unlike in UC, staining is more commonly focal and weak. GATA3 is also a useful maker when diagnosing metastatic UC to the lung.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982890      PMCID: PMC3444740          DOI: 10.1097/PAS.0b013e318260cde7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  19 in total

1.  Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas.

Authors:  O Kaufmann; J Volmerig; M Dietel
Journal:  Am J Clin Pathol       Date:  2000-05       Impact factor: 2.493

2.  Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer.

Authors:  Nadine T Gaisa; Till Braunschweig; Nina Reimer; Jörg Bornemann; Elke Eltze; Sabine Siegert; Marieta Toma; Luigi Villa; Arndt Hartmann; Ruth Knuechel
Journal:  Virchows Arch       Date:  2010-12-07       Impact factor: 4.064

3.  GATA Transcription Factors and Cancer.

Authors:  Rena Zheng; Gerd A Blobel
Journal:  Genes Cancer       Date:  2010-12

4.  Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.

Authors:  O Kaufmann; E Fietze; J Mengs; M Dietel
Journal:  Am J Clin Pathol       Date:  2001-12       Impact factor: 2.493

5.  Thrombomodulin expression in transitional cell carcinoma.

Authors:  N G Ordóñez
Journal:  Am J Clin Pathol       Date:  1998-09       Impact factor: 2.493

Review 6.  GATA-3 and the regulation of the mammary luminal cell fate.

Authors:  Hosein Kouros-Mehr; Jung-whan Kim; Seth K Bechis; Zena Werb
Journal:  Curr Opin Cell Biol       Date:  2008-03-21       Impact factor: 8.382

7.  Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.

Authors:  Ai-Ying Chuang; Angelo M DeMarzo; Robert W Veltri; Rajni B Sharma; Charles J Bieberich; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2007-08       Impact factor: 6.394

8.  Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.

Authors:  John P T Higgins; Gulsah Kaygusuz; Lingli Wang; Kelli Montgomery; Veronica Mason; Shirley X Zhu; Robert J Marinelli; Joseph C Presti; Matt van de Rijn; James D Brooks
Journal:  Am J Surg Pathol       Date:  2007-05       Impact factor: 6.394

9.  Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.

Authors:  Kazumasa Matsumoto; Takefumi Satoh; Akira Irie; Junichiro Ishii; Sadahito Kuwao; Masatsugu Iwamura; Shiro Baba
Journal:  Urology       Date:  2008-03-03       Impact factor: 2.649

10.  Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.

Authors:  Douglas C Parker; Andrew L Folpe; Julie Bell; Esther Oliva; Robert H Young; Cynthia Cohen; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

View more
  23 in total

Review 1.  The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.

Authors:  Ankur R Sangoi; Bijayee Shrestha; George Yang; Ourhay Mego; Andrew H Beck
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-04

2.  Loss of GATA3 in bladder cancer promotes cell migration and invasion.

Authors:  Yi Li; Hitoshi Ishiguro; Takashi Kawahara; Eiji Kashiwagi; Koji Izumi; Hiroshi Miyamoto
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

3.  GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.

Authors:  Natalie Banet; Allen M Gown; Ie-Ming Shih; Qing Kay Li; Richard B S Roden; Marisa R Nucci; Liang Cheng; Christopher G Przybycin; Niloofar Nasseri-Nik; Lee-Shu-Fune Wu; George J Netto; Brigitte M Ronnett; Russell Vang
Journal:  Am J Surg Pathol       Date:  2015-01       Impact factor: 6.394

4.  GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens.

Authors:  Yi Li; Hitoshi Ishiguro; Takashi Kawahara; Yurina Miyamoto; Koji Izumi; Hiroshi Miyamoto
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

5.  Non-invasive papillary urothelial carcinoma of the vagina: molecular analysis of a rare case identifies clonal relationship to non-invasive urothelial carcinoma of the bladder.

Authors:  Hind N Warzecha; Falko Fend; Julia Steinhilber; Harald Abele; Melanie Henes; Niklas Harland; Annette Staebler
Journal:  Virchows Arch       Date:  2017-06-07       Impact factor: 4.064

6.  GATA3 immunohistochemical expression in salivary gland neoplasms.

Authors:  Lauren E Schwartz; Shahnaz Begum; William H Westra; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2013-04-20

7.  HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.

Authors:  Justine Varinot; Olivier Cussenot; Morgan Roupret; Pierre Conort; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; Liang Cheng; Eva Compérat
Journal:  Virchows Arch       Date:  2013-10-22       Impact factor: 4.064

8.  GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.

Authors:  Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Janusz Rys; Piotr Czapiewski; Krzysztof Wazny; Renata Langfort; Piotr Waloszczyk; Wojciech Biernat; Jerzy Lasota; Zengfeng Wang
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

9.  The clinicopathological features of metastatic tumors of the bladder: analysis of 25 cases.

Authors:  Luhua Wang; Guoxin Song; Weiming Zhang; Zhihong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

10.  GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma.

Authors:  Meenatai Naik; B Vishal Rao; Daphne Fonseca; S Sudha Murthy; Ashwin Giridhar; Rakesh Sharma; Kvvn Raju; T Subramanyeswar Rao; Sundaram Challa
Journal:  Indian J Surg Oncol       Date:  2020-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.